Electronic Supplementary Material (ESI) for New Journal of Chemistry. This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2022

Co(П)/SpiroBox-catalyzed Enantioselective Mukaiyama-Mannich

Reaction for the Synthesis of Quaternary a-Amino Acid Derivatives

Yanshun Li, Nanxing Gao, Guorui Cao, Dawei Teng*

College of Chemical Engineering, Qingdao University of Science and Technology

E-mail: dteng@qust.edu.cn

Table of Contents

1. Experimental Section	S2
1.1. General	.S2
1.2. General procedure for synthesis of ligands L1a-L1c and L2	\$3
1.3. General procedure for synthesis of ligand L3	S5
1.4. General procedure for synthesis of ligand L4	S6
2. General procedure for asymmetric Mukaiyama-Mannich reaction	.88
3. NMR spectrum and HPLC trace of compounds	.S26
5. References	S84

1. Experimental Section

1.1. General

All the reagents were purchased from Aldrich, TCI, Energy chemical and other local suppliers, and used without purification. Toluene, methanol, dichloromethane, chloroform, acetonitrile and tetrahydrofuran were used without purification unless otherwise stated. All reactions were monitored by TLC. Chromatography refers to open column chromatography on silica gel (200-300mesh). ¹H NMR spectra were recorded on 500 or 400 MHz, ¹³C NMR spectra were recorded on 126 or 101 MHz by using a Bruker Avance spectrometer. Chemical shifts were reported in parts per million (δ) relative to tetramethylsilane (TMS). Mass spectra were performed on an Ultima Global spectrometer with an ESI source. Optical rotations were measured on Rudolph Autopol IV-Tautomatic polarimeter and reported as follows: $\left[\alpha\right]_{D}^{20}(c \text{ g}/100$ mL, solvent). Chiral HPLC analysis was performed using a Shimadzu LC-20AT UFLC. Substrates silvl enol ethers were synthesized according to the already reported literatures^[1]. Substrates cyclic *N*-sulfonyl ketimino ester were synthesized according to the known procedures^[2]. The (R)-indane-based chiral amino alcohol was synthesized according to reported literature^[3] and our pioneering studies^[4].

1.2. General procedure for synthesis of ligands L1a-L1c and L2



To a solution of substituted 2-pyridine carboxylic acid or 2-Quinoline carboxylic acid (2.62 mmol) in anhydrous DCM (10 mL) was added N-hydroxybenzotrizole (HOBT) (2.88)*N*-(3-dimethylaminopropyl)-*N*'-ethylcarbodiimide mmol). hydrochloride (EDCI-HCl) (2.88 mol), and triethylamine (4.32 mmol) at 0 °C sequentially. The reaction mixture was stirred at room temperature for 1 hour. Then chiral amino alcohol R-1 (2.62 mmol) was added and the reaction mixture was allowed warm to room temperature and stirred for 3 hours. The solvent was evaporated to obtain the intermediate R-2. The intermediate R-2 was used directly without further purification. To a solution of triphenylphosphine (3.14 mmol), and 2,3-dichloro-5,6-dicyano-1,4-benzoquinon (DDQ, 3.14 mmol) in DCM (10 mL) was added the intermediate *R*-2 slowly at 0 °C. The reaction mixture was warmed to room temperature and monitored by TLC. The reaction mixture was filtrated through celite, washed with 5% sodium hydroxide. The aqueous phase was extracted with DCM. The combined organic layers were dried over anhydrous sodium sulfate, filtrated, and concentrated under reduced pressure. The residue was purified by chromatography with petroleum ether/ethyl acetate 3:1 (v/v) to give L1a-L1c or L2.

(*R*)-2'-(Pyridin-2-yl)-2,3-dihydro-5'*H*-spiro[indene-1,4'-oxazole] (L1a) Yellow oil, $[\alpha]_D^{20} = +70.2$ (c = 0.4, MeOH), 49% yield. ¹H NMR (500 MHz, CDCl₃) δ 8.74 (d, *J* = 4.9 Hz, 1H), 8.13 (d, *J* = 7.9 Hz, 1H), 7.78 (t, *J* = 7.8 Hz, 1H), 7.43-7.40 (m, 1H), 7.27 (d, *J* = 11.5 Hz, 4H), 4.69 (d, *J* = 8.8 Hz, 1H), 4.59 (d, *J* = 8.8 Hz, 1H), 3.23-3.18 (m, 1H), 3.00-2.98 (m, 1H), 2.59-2.55 (m, 1H), 2.30-2.26 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 162.36, 149.96, 147.02, 145.93, 143.61, 136.83, 128.49, 127.39, 125.83, 124.92, 124.39, 123.60, 81.21, 79.12, 40.38, 30.44. HRMS (ESI): calcd for C₁₆H₁₄N₂O [M+Na]⁺: 273.1004, found 273.1008.

(*R*)-2'-(5-(Trifluoromethyl)pyridin-2-yl)-2,3-dihydro-5'*H*-spiro[indene-1,4'-oxa zole] (L1b) White solid, m.p.: 104.5-105.3 °C, $[\alpha]_D^{20} = +87.5$ (c = 0.2, MeOH), 55% yieid. ¹H NMR (500 MHz, CDCl₃) δ 8.90 (s, 1H), 8.17 (d, *J* = 8.2 Hz, 1H), 7.95 (dd, *J* = 8.3, 2.3 Hz, 1H), 7.23-7.12 (m, 4H), 4.64 (d, *J* = 8.8 Hz, 1H), 4.53 (d, *J* = 8.9 Hz, 1H), 3.17-3.11 (m, 1H), 2.92-2.89 (m, 1H), 2.53-2.47 (m, 1H), 2.23-2.18 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 161.09, 149.96, 146.62 (q, *J* = 4.1 Hz), 145.32, 143.46, 133.96 (q, *J* = 3.6 Hz), 128.49, 128.10 (q, *J* = 33.2 Hz), 127.27, 124.83, 123.94, 123.31, 123.14 (q, *J* = 273.4 Hz), 81.24, 79.09, 40.14, 30.25. HRMS (ESI): calcd for C₁₇H₁₃F₃N₂O [M+Na]⁺ : 341.0878, found 341.0883.

(R)-2'-(5-Methoxypyridin-2-yl)-2,3-dihydro-5'H-spiro[indene-1,4'-oxazole]

(L1c) White solid, m.p.: 107.7-108.5 °C, $[\alpha]_D^{20} = +46.4$ (c = 0.2, MeOH), 56% yield. ¹H NMR (500 MHz, CDCl₃) δ 8.40 (d, J = 2.9 Hz, 1H), 8.08 (d, J = 8.7 Hz, 1H), 7.28-7.20 (m, 5H), 4.65 (d, J = 8.7 Hz, 1H), 4.56 (d, J = 8.4 Hz, 1H), 3.92 (s, 3H), 3.24-3.18 (m, 1H), 3.01-2.95 (m, 1H), 2.59-2.54 (m, 1H), 2.30-2.25 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 161.96, 157.23, 145.95, 143.37, 139.11, 137.81, 128.20, 127.16, 125.15, 124.69, 123.41, 120.08, 80.91, 78.87, 55.75, 40.20, 30.24. HRMS (ESI): calcd for C₁₇H₁₆N₂O₂ [M+H]⁺ : 281.1290, found 281.1288, [M+Na]⁺: 303.1109, found 303.1106.

(*R*)-2'-(Quinolin-2-yl)-2,3-dihydro-5'*H*-spiro[indene-1,4'-oxazole] (L2) White solid, m.p.: 132.5-133.2 °C, $[\alpha]_D^{20} = +89.7$ (c = 0.3, MeOH), 67% yield. ¹H NMR (500 MHz, CDCl₃) δ 8.31 (d, *J* = 8.5 Hz, 1H), 8.27-8.22 (m, 2H), 7.87 (d, *J* = 8.2 Hz, 1H), 7.78 (t, *J* = 7.8 Hz, 1H), 7.62 (t, *J* = 7.5 Hz, 1H), 7.29-7.26 (m, 4H), 4.76 (d, *J* = 8.8 Hz, 1H), 4.67 (d, *J* = 8.8 Hz, 1H), 3.25-3.19 (m, 1H), 3.04-3.00 (m, 1H), 2.64-2.59 (m, 1H), 2.34-2.29 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 162.51, 147.63, 146.95, 145.74, 143.44, 136.72, 130.38, 130.08, 128.83, 128.38, 127.99, 127.57, 127.30, 124.80, 123.49, 121.14, 81.17, 79.27, 40.30, 30.30. HRMS (ESI): calcd for C₁₆H₁₄N₂O [M+Na]⁺: 323.1160, found 323.1162.

1.3. General procedure for synthesis of ligand L3



A 100-ml three-necked round-bottomed flask fitted with a reflux condenser was charged with 2, 2-dimethyl malononitrile (1.31 mmol), Zn(OTf)₂ (1.31 mmol) and

chiral amino alcohol *R*-1 (2.62 mmol). The system was purged with argon and toluene (50 mL) was added. The solution was heated under reflux for 48 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography with petroleum ether/ethyl acetate 3:1 (v/v) to give L3.

Bis((*R*)-2,3-dihydro-5'*H*-spiro[indene-1,4'-oxazol]-2'-yl)propane (L3) White solid, m.p.: 66.1-67.5 °C, $[\alpha]_D^{20} = +18.4$ (c= 0.3, MeOH), 69% yield. ¹H NMR (500 MHz, CDCl₃) δ 7.25-7.16 (m, 8H), 4.40 (d, *J* = 8.5 Hz, 2H), 4.34 (d, *J* = 8.5 Hz, 2H), 3.13-3.07 (m, 2H), 2.97-2.90 (m, 2H), 2.53-2.47 (m, 2H), 2.21-2.15 (m, 2H), 1.64 (s, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 169.05, 146.30, 142.98, 128.11, 127.19, 124.60, 123.31, 80.28, 79.48, 39.58, 38.72, 30.21, 24.66. HRMS (ESI): calcd for C₂₅H₂₇N₂O₂ [M+H]⁺: 387.2073, found 387.2065, [M+Na]⁺: 409.1892, found 409.1881.

1.4. General procedure for synthesis of ligand L4



Pyridine-2,6-dicarboxylic acid (5 mmol) was treated with SOCl₂ (10 mL) at 80 °C over night. Excess SOCl₂ was then removed under reduced pressure to give the acid

chloride as a white solid (100% yield). A solution of crude 2,6-pyridine carbonyl dichloride in DCM was slowly added to a solution of *R*-1 (10 mmol) and triethylamine (30 mmol) in DCM (20 mL) at 0 °C for 2h. The reaction mixture was warmed to room temperature, SOCl₂ (20 mmol) was added. The mixture was heated to reflux for 2 h and then poured into ice water. The organic layer was washed with brine and Na₂CO₃ aqueous and then dried over anhydrous Na₂SO₄. After evaporating the solvent, The solid was treated with alcohol (20 mL) and NaOH (40 mmol) at room temperature for 24h. The mixture was extracted with DCM and brine, the organic layer was dried over Na₂SO₄. After evaporating the solvent, the crude product was purified by chromatography with ether/ethyl acetate 2:1 (v/v) to give L4 as white solid.

2,6-Bis((*R*)-**2,3-dihydro-5**'*H*-spiro[indene-**1,4**'-oxazol]-**2**'-yl)pyridine (L4) White solid, m.p.: 177.1-176.4 °C, $[\alpha]_D^{20} = +16.5$ (c = 0.3, MeOH), 47% yield. ¹H NMR (500 MHz, CDCl₃) δ 8.28 (d, *J* = 7.8 Hz, 2H), 7.86 (t, *J* = 7.8 Hz, 1H), 7.25 (dd, *J* = 14.4, 2.5 Hz, 8H), 4.68 (d, *J* = 8.9 Hz, 2H), 4.61 (d, *J* = 8.8 Hz, 2H), 3.20-3.14 (m, 2H), 3.01-2.95 (m, 2H), 2.55-2.50 (m, 2H), 2.29-2.24 (m, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 161.90, 146.81, 145.60, 143.40, 137.40, 128.39, 127.30, 126.27, 124.81, 123.46, 81.01, 79.19, 40.33, 30.23. HRMS (ESI): calcd for C₂₇H₂₃N₃O₂ [M+H]⁺ : 422.1869, found 422.1866, [M+Na]⁺ : 444.1688, found 444.1679. 2. General procedure for asymmetric Mukaiyama-Mannich reaction

L3 (2.3 mg, 0.006 mmol) and Co(ClO₄)₂.6H₂O (1.8 mg, 0.005 mmol) were dissolved in CHCl₃ (1.0 mL) in a Schlenk tube under an Ar atmosphere at room temperature for 1h. Then cyclic *N*-sulfonyl ketimino ester (0.1 mmol) was added and the mixture was stirred at 0 °C for 30 min before enol silyl ether (0.2 mmol) was added. The mixture was stirred at 0 °C until the reaction was completed (monitored by TLC). The solvent was removed under vacuum, and the residue was purified by chromatography on silica gel with petroleum ether/ethyl acetate 3:1 (v/v) to give the product.



(*R*)-ethyl 3-(2-oxo-2-phenylethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1aa) White solid, m.p.: 83.5-84.9 °C, $[\alpha]_D^{20} = +155.7$ (c = 0.15, DCM), 98% yield and 99% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 15.142 min for (*S*)-isomer (minor), t_r = 19.892 min for (*R*)-isomer (major). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.95-7.89 (m, 2H), 7.84 (dt, *J* = 7.6, 1.0 Hz, 1H), 7.71 (d, *J* = 3.7 Hz, 2H), 7.67-7.57 (m, 2H), 7.47 (t, *J* = 7.8 Hz, 2H), 6.07 (s, 1H), 4.40-4.25 (m, 2H), 4.09 (d, *J* = 17.7 Hz, 1H), 3.73 (d, *J* = 17.7 Hz, 1H), 1.31 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 195.95, 169.61, 136.95, 135.62, 134.02, 133.66, 130.83, 128.81, 128.21, 124.25, 121.91, 65.48, 63.52, 49.16, 13.96. HRMS (ESI): calcd for $C_{18}H_{17}NO_5S [M+Na]^+$: 382.0725, found 382.0721.



(*R*)-ethyl 5-methyl-3-(2-oxo-2-phenylethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1ba) White solid, m.p.: 90.8-92.2 °C, $[\alpha]_D^{20} = +134.6$ (c = 0.22, DCM), 98% yield and 99% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 11.937 min for (*S*)-isomer (minor), t_r = 16.372 min for (*R*)-isomer (major). ¹H NMR (500 MHz, Chloroform-*d*) δ 7.85 (d, *J* = 7.7 Hz, 2H), 7.64 (d, *J* = 8.0 Hz, 1H), 7.53 (t, *J* = 7.4 Hz, 1H), 7.45-7.33 (m, 4H), 5.96 (s, 1H), 4.32-4.16 (m, 1H), 4.25-4.18 (m, 1H), 4.02 (d, *J* = 17.7 Hz, 1H), 3.63 (d, *J* = 17.7 Hz, 1H), 2.43 (s, 3H), 1.25 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 196.09, 169.75, 144.88, 137.20, 135.62, 134.00, 132.85, 131.77, 128.79, 128.20, 124.39, 121.63, 65.32, 63.45, 49.31, 21.90, 13.97. HRMS (ESI): calcd for C₁₉H₁₉NO₅S [M+Na]⁺:396.0082, found 396.0077.



(*R*)-ethyl 5-methoxy-3-(2-oxo-2-phenylethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1ca) White solid, m.p.: 144.1-145.6 °C, $[\alpha]_D^{20} =$ +174.4 (c = 0.35, DCM), 98% yield and 98% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: $t_r = 15.062 \text{ min for } (S)\text{-isomer (minor)}, t_r = 19.906 \text{ min for } (R)\text{-isomer (major)}. ¹H NMR (400 MHz, Chloroform-$ *d* $) <math>\delta$ 7.91 (d, J = 7.0 Hz, 2H), 7.73 (d, J = 8.2 Hz, 1H), 7.60 (t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.7 Hz, 2H), 7.12 (d, J = 8.2 Hz, 2H), 6.03 (s, 1H), 4.43-4.24 (m, 2H), 4.05 (d, J = 17.7 Hz, 1H), 3.91 (s, 3H), 3.74 (d, J = 17.7 Hz, 1H), 1.32 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 195.97, 169.61, 163.94, 139.54, 135.63, 134.01, 128.81, 128.21, 127.58, 123.31, 117.24, 108.60, 65.17, 63.49, 56.06, 49.33, 14.02. HRMS (ESI): calcd for $C_{19}H_{19}NO_6S$ [M+Na]⁺:412.0831, found 412.0822



(*R*)-ethyl 5-(*tert*-butyl)-3-(2-oxo-2-phenylethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1da) White solid, m.p.: 136.7-137.9 °C, $[\alpha]_D^{20}$ = +136.9 (c = 0.17, DCM), 97% yield and 98% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 7.487 min for (*S*)-isomer (minor), t_r = 13.062 min for (*R*)-isomer (major).¹H NMR (500 MHz, Chloroform-*d*) δ 7.86 (d, *J* = 7.7 Hz, 2H), 7.68 (d, *J* = 8.3 Hz, 1H), 7.60 (d, *J* = 7.5 Hz, 2H), 7.53 (t, *J* = 7.4 Hz, 1H), 7.40 (t, *J* = 7.6 Hz, 2H), 5.98 (s, 1H), 4.38-4.31 (m, 1H), 4.22-4.15 (m, 1H), 3.99 (d, *J* = 17.7 Hz, 1H), 3.68 (d, *J* = 17.7 Hz, 1H), 1.31 (s, 9H), 1.24 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 196.06, 169.75, 158.15, 137.08, 135.66, 133.99, 132.84, 128.79, 128.50, 128.24, 121.42, 120.61, 65.52, 63.33, 49.26, 35.63, 31.21, 14.05. HRMS (ESI): calcd for C₂₂H₂₅NO₅S [M+Na]⁺ : 438.1351, found 438.1344.



(*R*)-ethyl 5-chloro-3-(2-oxo-2-phenylethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1ea) White solid, m.p.: 87.8-88.6 °C, $[\alpha]_D^{20} = +139.3$ (c = 0.18, DCM), 99% yield and 99% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 15.386 min for (*S*)-isomer (minor), t_r = 21.657 min for (*R*)-isomer (major). ¹H NMR (500 MHz, Chloroform-*d*) δ 7.92 (d, *J* = 6.9 Hz, 2H), 7.77 (d, *J* = 8.3 Hz, 1H), 7.68 (d, *J* = 1.7 Hz, 1H), 7.65-7.57 (m, 2H), 7.48 (t, *J* = 7.8 Hz, 2H), 6.11 (s, 1H), 4.43-4.27 (m, 2H), 4.05 (d, *J* = 17.5 Hz, 1H), 3.74 (d, *J* = 17.6 Hz, 1H), 1.33 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 195.64, 169.11, 140.14, 139.00, 135.45, 134.21, 134.15, 131.33, 128.86, 128.23, 124.59, 123.11, 65.10, 63.83, 49.05, 13.96. HRMS (ESI): calcd for C₁₈H₁₆CINO₅S [M+Na]⁺ :416.0335, found 416.0326.



(*R*)-ethyl 3-(2-oxo-2-phenylethyl)-5-(trifluoromethyl)-2,3-dihydrobenzo[*d*] isothiazole-3-carboxylate 1,1-dioxide (1fa) White solid, m.p.: 99.3-100.7 °C, $[\alpha]_D^{20} = +117.7$ (c = 0.32, DCM), 69% yield and 99% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 8.895 min for (*S*)-isomer (minor), t_r = 16.202 min for (*R*)-isomer (major). ¹H NMR (500 MHz, Chloroform-*d*) δ 7.98 (d, J = 7.5 Hz, 2H), 7.95-7.89 (m, 3H), 7.62 (t, J = 7.4 Hz, 1H), 7.49 (t, J = 7.8 Hz, 2H), 6.20 (s, 1H), 4.45-4.39 (m, 1H), 4.35-4.28 (m, 1H), 4.10 (d, J = 17.6 Hz, 1H), 3.77 (d, J = 17.6 Hz, 1H), 1.33 (t, J = 7.1 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 196.08, 169.50, 139.58, 138.62, 136.30 (d, J = 33.4 Hz), 135.92, 134.77, 129.43, 128.80, 128.70 (q, J = 3.5 Hz), 123.39, 122.44 (q, J = 274.7 Hz), 122.29 (q, J = 3.8 Hz), 65.94, 64.47, 49.50, 14.47. HRMS (ESI): calcd for C₁₉H₁₆F₃NO₅S [M+Na]⁺:450.0599, found 450.0591.



(*R*)-ethyl 3-(2-oxo-2-(4-tolyl)ethyl)-2,3-dihydrobenzo[*d*] isothiazole -3-carboxylate 1,1-dioxide (1ab) White solid, m.p.: 76.2-77.7 °C, $[\alpha]_D^{20} = +47.9$ (c = 0.16, DCM), 99% yield and 96% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 20.138 min for (*S*)-isomer (minor), t_r = 22.912 min for (*R*)-isomer (major). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.42 (s, 1H), 7.81 (dd, *J* = 15.2, 8.0 Hz, 3H), 7.75-7.68 (m, 2H), 7.64-7.59 (m, 1H), 7.26 (d, *J* = 8.0 Hz, 2H), 4.25 (d, *J* = 18.1 Hz, 1H), 4.09-3.99 (m, 2H), 3.53 (d, *J* = 18.5 Hz, 1H), 2.30 (s, 3H), 1.05 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 195.59, 169.74, 144.36, 136.16, 135.04, 133.43, 133.03, 130.74, 129.31, 128.27, 124.76, 120.97, 64.91, 61.87, 49.09, 21.16, 13.72. HRMS (ESI): calcd for C₁₉H₁₉NO₅S [M+Na]⁺ :396.0882, found 396.0877.



(*R*)-ethyl 3-(2-(4-methoxyphenyl)-2-oxoethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1ac) White solid, m.p.: 66.3-67.6 °C, $[\alpha]_D^{20} = +79.8$ (c = 0.12, DCM), 96% yield and 99% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 22.639 min for (*R*)-isomer (major), t_r = 29.657 min for (*S*)-isomer (minor). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.89 (d, *J* = 8.9 Hz, 2H), 7.84 (d, *J* = 7.4 Hz, 1H), 7.70 (d, *J* = 2.5 Hz, 2H), 7.66-7.62 (m, 1H), 6.93 (d, *J* = 8.9 Hz, 2H), 6.07 (s, 1H), 4.40-4.23 (m, 2H), 4.04 (d, *J* = 17.5 Hz, 1H), 3.88 (s, 3H), 3.68 (d, *J* = 17.5 Hz, 1H), 1.31 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 194.36, 169.73, 164.20, 137.01, 135.59, 133.61, 130.76, 130.57, 128.71, 124.28, 121.86, 113.97, 65.60, 63.43, 55.56, 48.83, 13.96. HRMS (ESI): calcd for C₁₉H₁₉NO₆S [M+Na]⁺:412.0831, found 412.0822.



(*R*)-ethyl 3-(2-(4-fluorophenyl)-2-oxoethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1ad) White solid, m.p.: 71.4-72.3 °C, $[\alpha]_D^{20} = +123.9$ (c = 0.27, DCM), 93% yield and 97% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 13.268 min for (*R*)-isomer (major), t_r = 19.243 min for

(*S*)-isomer (minor). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.99-7.92 (m, 2H), 7.84 (d, J = 7.5 Hz, 1H), 7.70 (d, J = 4.4 Hz, 2H), 7.68-7.62 (m, 1H), 7.14 (t, J = 8.6 Hz, 2H), 6.05 (s, 1H), 4.41-4.25 (m, 2H), 4.04 (d, J = 17.6 Hz, 1H), 3.70 (d, J = 17.6 Hz, 1H), 1.32 (t, J = 7.1 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 194.37, 169.51, 166.25 (d, J = 256.5 Hz), 136.88, 135.65, 133.68, 132.12 (d, J = 3.0 Hz), 130.99, 130.90 (d, J = 5.5 Hz), 124.21, 121.92, 116.02 (d, J = 22.0 Hz), 65.44, 63.58, 49.00, 13.96. HRMS (ESI): calcd for C₁₈H₁₆FNO₅S [M+Na]⁺: 400.0631, found 400.0623.



(*R*)-ethyl 3-(2-(4-chlorophenyl)-2-oxoethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1ae) White solid, m.p.: 88.1-89.3 °C, $[\alpha]_D^{20} = +119.1$ (c = 0.35, DCM), 98% yield and 97% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 15.342 min for (*R*)-isomer (major), t_r = 21.386 min for (*S*)-isomer (minor). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.89-7.81 (m, 3H), 7.70 (d, J = 3.1 Hz, 2H), 7.67-7.63 (m, 1H), 7.45 (d, J = 8.3 Hz, 2H), 6.05 (s, 1H), 4.41-4.25 (m, 2H), 4.03 (d, J = 17.6 Hz, 1H), 3.69 (d, J = 17.4 Hz, 1H), 1.31 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 194.79, 169.46, 140.59, 136.84, 135.63, 133.95, 133.71, 130.90, 129.62, 129.17, 124.22, 121.92, 65.40, 63.61, 49.03, 13.97. HRMS (ESI): calcd for C₁₈H₁₆ClNO₅S [M+Na]⁺: 416.0335, found 416.0329.



(*R*)-ethyl 3-(2-oxo-2-(4-(trifluoromethyl)phenyl)ethyl)-2,3-dihydrobenzo[*d*] isothiazole-3-carboxylate 1,1-dioxide (1af) White solid, m.p.: 54.4-55.6 °C, $[\alpha]_D^{20}$ = +106.3 (c = 0.22, DCM), 85% yield and 99% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 15.730 min for (*R*)-isomer (major), t_r = 21.503 min for (*S*)-isomer (minor). ¹H NMR (500 MHz, Chloroform-*d*) δ 7.96 (d, *J* = 8.2 Hz, 2H), 7.78 (d, *J* = 7.7 Hz, 1H), 7.67 (d, *J* = 8.2 Hz, 2H), 7.64 (d, *J* = 2.5 Hz, 2H), 7.61-7.57 (m, 1H), 5.99 (s, 1H), 4.35-4.20 (m, 2H), 3.99 (d, *J* = 17.7 Hz, 1H), 3.68 (d, *J* = 17.8 Hz, 1H), 1.25 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 194.65, 168.84, 137.75, 136.29, 135.18, 134.71 (q, *J* = 32.6 Hz), 133.26, 130.47, 128.10, 125.40 (q, *J* = 3.8 Hz), 123.69, 122.91 (q, *J* = 273.4 Hz), 121.45, 64.83, 63.20, 48.73, 13.46. HRMS (ESI): calcd for C₁₉H₁₆F₃NO₅S [M+Na]⁺: 450.0599, found 450.0592.



(*R*)-ethyl 3-(2-oxo-2-(3-tolyl)ethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1ag) White solid, m.p.: 77.9-79.3 °C, $[\alpha]_D^{20} = +122.1$ (c = 0.28, DCM), 99% yield and 94% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 15.028 min for (*S*)-isomer (minor), t_r = 24.494 min for (*R*)-isomer (major). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.54 (s, 1H), 7.92-7.78 (m, 5H), 7.75-7.69 (m, 1H), 7.51 (d, J = 7.5 Hz, 1H), 7.44 (t, J = 7.6 Hz, 1H), 4.37 (d, J = 18.4 Hz, 1H), 4.20-4.19 (m, 2H), 3.66 (d, J = 18.4 Hz, 1H), 2.38 (s, 3H), 1.15 (t, J = 7.1 Hz, 3H). ¹³C NMR (126 MHz, DMSO- d_6) δ 196.65, 170.21, 138.75, 136.66, 135.99, 135.55, 134.92, 133.94, 131.26, 129.19, 129.16, 125.76, 125.27, 121.48, 65.39, 62.39, 49.75, 21.23, 14.23. HRMS (ESI): calcd for C₁₉H₁₉NO₅S [M+Na]⁺:396.0882, found 396.0877.



(*R*)-ethyl 3-(2-(3-methoxyphenyl)-2-oxoethyl)-2,3-dihydrobenzo[*d*] isothiazole-3-carboxylate 1,1-dioxide (1ah) White solid, m.p.: $65.1-66.5 \, ^{\circ}$ C, $[\alpha]_D^{20}$ = +159.5 (c = 0.13, DCM), 98% yield and 95% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 70:30 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 13.381 min for (*S*)-isomer (minor), t_r = 40.464 min for (*R*)-isomer (major). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.53 (s, 1H), 7.89 (d, *J* = 7.7 Hz, 1H), 7.82 (q, *J* = 8.2 Hz, 2H), 7.73 (d, *J* = 6.8 Hz, 1H), 7.61 (d, *J* = 7.7 Hz, 1H), 7.48 (dd, *J* = 17.1, 9.1 Hz, 2H), 7.26 (dd, *J* = 8.2, 2.7 Hz, 1H), 4.39 (d, *J* = 18.5 Hz, 1H), 4.20-4.09 (m, 2H), 3.83 (s, 3H), 3.69 (d, *J* = 18.6 Hz, 1H), 1.15 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 196.47, 170.23, 159.93, 137.35, 136.61, 135.54, 133.94, 131.26, 130.45, 125.29, 121.48, 121.14, 120.58, 112.95, 65.42, 62.40, 55.87, 49.77, 14.22. HRMS (ESI): calcd for C₁₉H₁₉NO₆S [M+Na]⁺: 412.0831, found 412.0823.



(*R*)-ethyl 3-(2-(3-chlorophenyl)-2-oxoethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1ai) White solid, m.p.: 81.1-82.7 °C, $[\alpha]_D^{20} = +109.8$ (c = 0.16, DCM), 97% yield and 95% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 21.784 min for (*S*)-isomer (minor), t_r = 33.071 min for (*R*)-isomer (major). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.89 (s, 1H), 7.84 (d, *J* = 7.9 Hz, 1H), 7.79 (d, *J* = 7.9 Hz, 1H), 7.70 (d, *J* = 2.9 Hz, 2H), 7.67-7.63 (m, 1H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.42 (t, *J* = 7.8 Hz, 1H), 6.04 (s, 1H), 4.41-4.25 (m, 2H), 4.04 (d, *J* = 17.7 Hz, 1H), 3.70 (d, *J* = 17.7 Hz, 1H), 1.32 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 194.77, 169.40, 137.09, 136.80, 135.66, 135.21, 133.93, 133.73, 130.92, 130.18, 128.31, 126.30, 124.22, 121.94, 65.34, 63.64, 49.16, 13.97. HRMS (ESI): calcd for C₁₈H₁₆ClNO₅S [M+Na]⁺: 416.0335, found 416.0326.



(*R*)-ethyl 3-(2-oxo-2-(2-tolyl)ethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1aj) White solid, m.p.: 66.7-67.7 °C, $[\alpha]_D^{20} = +102.9$ (c = 0.37, DCM), 95% yield and 97% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 11.334 min for (*S*)-isomer (minor), t_r = 16.863 min for (*R*)-isomer (major). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.83 (d, *J* = 7.6 Hz, 1H), 7.72-7.60 (m, 4H), 7.41 (t, J = 7.5 Hz, 1H), 7.31-7.21 (m, 2H), 6.09 (s, 1H), 4.41-4.27 (m, 2H), 4.04 (d, J = 17.7 Hz, 1H), 3.65 (d, J = 17.7 Hz, 1H), 2.53 (s, 3H), 1.33 (t, J = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 198.81, 169.33, 138.80, 136.63, 135.35, 135.26, 133.24, 131.97, 131.93, 130.39, 128.67, 125.48, 123.85, 121.51, 65.32, 63.11, 51.03, 21.20, 13.62. HRMS (ESI): calcd for C₁₉H₁₉NO₅S [M+Na]⁺: 396.0882, found 396.0877.



(*R*)-ethyl 3-(2-(2-methoxyphenyl)-2-oxoethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1ak) White solid, m.p.: 99.7-100.8 °C, $[\alpha]_D^{20}$ = +143.6 (c = 0.23, DCM), 98% yield and 95% ee, determined by chiral HPLC analysis (Chiralcel AD-H hexane/isopropanol, 70:30 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 38.396 min for (*S*)-isomer (minor), t_r = 50.468 min for (*R*)-isomer (major). ¹H NMR (500 MHz, Chloroform-*d*) & 7.86 (dd, *J* = 7.9, 1.9 Hz, 1H), 7.82 (d, *J* = 7.7 Hz, 1H), 7.69 (d, *J* = 5.6 Hz, 2H), 7.64-7.61 (m 1H), 7.54-7.47 (m, 1H), 7.03 (t, *J* = 7.6 Hz, 1H), 6.96 (d, *J* = 8.3 Hz, 1H), 6.05 (s, 1H), 4.38-4.24 (m, 2H), 4.12 (d, *J* = 18.4 Hz, 1H), 3.86 (s, 3H), 3.74 (d, *J* = 18.6 Hz, 1H), 1.30 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) & 196.32, 169.48, 158.98, 136.71, 135.03, 134.51, 133.07, 130.41, 130.11, 125.26, 123.88, 121.29, 120.35, 111.19, 65.42, 62.77, 55.07, 54.01, 13.48. HRMS (ESI): calcd for C₁₉H₁₉NO₆S [M+Na]⁺: 412.0831, found 412.0822.



(*R*)-ethyl 3-(2-(2-bromophenyl)-2-oxoethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1al) White solid, m.p.: 75.4-77.1 °C, $[\alpha]_D^{20} = +110.7$ (c = 0.22, DCM), 93% yield and 96% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 18.290 min for (*S*)-isomer (minor), t_r = 36.347 min for (*R*)-isomer (major). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.82 (d, *J* = 7.5 Hz, 1H), 7.68 (d, *J* = 4.2 Hz, 2H), 7.63 (dd, *J* = 8.0, 4.3 Hz, 2H), 7.52 (dd, *J* = 7.7, 1.8 Hz, 1H), 7.39 (t, *J* = 7.5 Hz, 1H), 7.33 (td, *J* = 7.6, 1.8 Hz, 1H), 6.07 (s, 1H), 4.43-4.32 (m, 2H), 4.09 (d, *J* = 17.9 Hz, 1H), 3.67 (d, *J* = 18.0 Hz, 1H), 1.36 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 199.11, 169.28, 139.34, 136.84, 135.65, 134.10, 133.68, 132.56, 130.86, 129.32, 127.63, 124.20, 121.88, 119.12, 65.54, 63.74, 52.29, 14.04. HRMS (ESI): calcd for C₁₈H₁₆BrNO₅S [M+Na]⁺: 459.9830, found 459.9821.



(*R*)-ethyl 5-methoxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)-2,3-dihydrobenzo[*d*] isothiazole-3-carboxylate 1,1-dioxide (1am) White solid, m.p.: 131.1-132.3 °C, $[\alpha]_D^{20} = +147.7$ (c = 0.14, DCM), 97% yield and 97% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 18.830 min for (*R*)-isomer (major), t_r = 28.530 min for (*S*)-isomer (minor). ¹H NMR (500 MHz, DMSO- d_6) δ 8.29 (s, 1H), 7.98 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 8.5 Hz, 1H), 7.27 (s, 1H), 7.23 (d, J = 8.7 Hz, 1H), 7.05 (d, J = 8.4 Hz, 2H), 4.38 (d, J = 18.3 Hz, 1H), 4.24-4.04 (m, 2H), 3.89 (s, 3H), 3.85 (s, 3H), 3.56 (d, J = 18.3 Hz, 1H), 1.15 (t, J = 7.0 Hz, 3H). ¹³C NMR (126 MHz, DMSO- d_6) δ 194.93, 170.25, 164.08, 163.50, 139.34, 131.05, 128.98, 127.66, 122.99, 117.89, 114.44, 109.36, 65.21, 62.31, 56.53, 56.08, 49.49, 14.28. HRMS (ESI): calcd for C₂₀H₂₁NO₇S [M+Na]⁺ : 442.0936, found 442.0929.



(*R*)-ethyl 3-(2-(4-chlorophenyl)-2-oxoethyl)-5-methoxy-2,3-dihydrobenzo[d] isothiazole-3-carboxylate 1,1-dioxide (1an) White solid, m.p.: 103.8-104.9 °C, $[\alpha]_{D}^{20} = +139.2$ (c = 0.35, DCM), 98% yield and 99% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: $t_r = 16.984$ min for (S)-isomer (minor), $t_r = 20.709$ min for (R)-isomer (major). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.26 (s, 1H), 7.94 (d, *J* = 8.5 Hz, 2H), 7.70 (d, *J* = 8.6 Hz, 1H), 7.54 (d, *J* = 8.6 Hz, 2H), 7.20 (d, J = 2.3 Hz, 1H), 7.14 (dd, J = 8.6, 2.3 Hz, 1H), 4.39 (d, J =18.8 Hz, 1H), 4.12-3.95 (m, 2H), 3.80 (s, 3H), 3.54 (d, J = 18.5 Hz, 1H), 1.05 (t, J =7.1 Hz, 3H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 195.75, 170.14, 163.53, 139.26, 134.70, 130.60, 129.39, 127.62, 123.01, 117.96, 109.35, 65.09, 62.40, 56.55, 49.65, 14.27. HRMS (ESI): calcd for $C_{19}H_{18}CINO_6S [M+Na]^+$: 446.0441, found 446.0433



(*R*)-ethyl 4-(2-oxo-2-phenylethyl)-3,4-dihydrobenzo[*e*][1,2,3]oxathiazine-4carboxylate 2,2-dioxide (1ga) White solid, m.p.: 97.7-98.5 °C, $[\alpha]_D^{20} = -33.1$ (c = 0.35, DCM), 83% yield and 73% ee, determined by chiral HPLC analysis (Chiralcel AD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 21.361 min for (*R*)-isomer (major), t_r = 30.033 min for (*S*)-isomer (minor). ¹H NMR (500 MHz, Chloroform-*d*) δ 7.94 (d, *J* = 8.5 Hz, 2H), 7.65 (d, *J* = 8.1 Hz, 1H), 7.60 (t, *J* = 7.4 Hz, 1H), 7.48 (t, *J* = 7.8 Hz, 2H), 7.44-7.38 (m, 1H), 7.27 (d, *J* = 7.6 Hz, 2H), 7.09 (d, *J* = 8.2 Hz, 1H), 6.43 (s, 1H), 4.56 (d, *J* = 17.9 Hz, 1H), 4.37 (q, *J* = 7.1 Hz, 2H), 3.83 (d, *J* = 17.9 Hz, 1H), 1.32 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 195.23, 169.43, 150.74, 135.96, 133.87, 130.89, 128.80, 128.19, 127.31, 125.85, 120.03, 119.45, 99.99, 65.27, 63.94, 47.07, 13.90. HRMS (ESI): calcd for C₁₈H₁₇NO₆S [M+Na]⁺: 398.0674, found 398.066.



(*R*)-2-(2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-4-yl)-1-phenylethanon e (1ha) White solid, m.p.: 79.2-81.1 °C, , $[\alpha]_D^{20} = -11.2$ (c = 0.35, DCM), 56% yield and 16% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r =

12.003 min for (*R*)-isomer (major), $t_r = 14.367$ min for (*S*)-isomer (minor). ¹H NMR (500 MHz, Chloroform-*d*) δ 7.98 (d, J = 6.9 Hz, 2H), 7.63 (t, J = 7.4 Hz, 1H), 7.50 (t, J = 7.7 Hz, 2H), 7.34-7.31 (m 1H), 7.15 (d, J = 4.4 Hz, 2H), 7.07 (d, J = 8.3 Hz, 1H), 5.84 (d, J = 8.2 Hz, 1H), 5.42 (td, J = 7.6, 3.7 Hz, 1H), 4.29 (dd, J = 18.2, 7.2 Hz, 1H), 3.43 (dd, J = 18.2, 3.8 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 197.77, 151.24, 136.14, 134.16, 129.62, 128.92, 128.25, 125.95, 125.47, 121.61, 119.14, 53.67, 41.80. HRMS (ESI): calcd for C₁₅H₁₃NO₄S [M+Na]⁺: 326.0463, found 326.0459.



(*R*)-methyl 3-(2-oxo-2-phenylethyl)-2,3-dihydrobenzo[*d*]isothiazole

-3-carboxylate 1,1-dioxide (1ia) White solid, m.p.: 129.4-130.5 °C, $[α]_D^{20}$ = +109.4 (c = 0.53, DCM), 98% yield and 98% ee, determined by chiral HPLC analysis (Chiralcel AD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 22.754 min for (*S*)-isomer (minor), t_r = 44.140 min (major) for (*R*)-isomer. ¹H NMR (500 MHz, Chloroform-*d*) δ 7.91 (d, *J* = 4.9 Hz, 2H), 7.84 (dd, *J* = 7.7, 3.4 Hz, 1H), 7.71 (t, *J* = 3.9 Hz, 2H), 7.67-7.64 (m, 1H), 7.60 (q, *J* = 4.4 Hz, 1H), 7.49-7.45 (m, 2H), 6.09 (s, 1H), 4.12 (dd, *J* = 17.8, 3.5 Hz, 1H), 3.86 (d, *J* = 3.6 Hz, 3H), 3.73 (dd, *J* = 17.8, 3.5 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 196.11, 170.25, 136.64, 135.50, 134.10, 133.74, 130.90, 128.82, 128.24, 126.42, 124.31, 121.91, 65.43, 54.15, 49.28. HRMS (ESI): calcd for C₁₇H₁₅NO₅S [M+Na]⁺: 368.0569, found 368.0568.



(*R*)-2-(1,1-dioxido-2,3-dihydrobenzo[*d*]isothiazol-3-yl)-1-phenylethanone (1ja) White solid, m.p.: 158.5-159.8 °C, $[\alpha]_{D}^{20} = +139.2$ (c = 0.35, DCM), 94% yield and 66% ee, determined by chiral HPLC analysis (Chiralcel AD-H hexane/isopropanol, 80:20 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 38.289 min for (*S*)-isomer (minor), t_r = 46.120 min (major) for (*R*)-isomer. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.00-7.86 (m, 3H), 7.74 (d, *J* = 7.8 Hz, 1H), 7.67-7.60 (m, 2H), 7.58 (t, *J* = 7.3 Hz, 1H), 7.53-7.49 (m, 1H), 7.46 (t, *J* = 7.8 Hz, 2H), 5.11 (dd, *J* = 9.1, 4.3 Hz, 1H), 3.61 (dd, *J* = 17.7, 3.2 Hz, 1H), 3.41 (dd, *J* = 17.7, 9.6 Hz, 1H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 196.87, 140.55, 136.36, 136.27, 133.51, 132.88, 129.29, 128.89, 128.76, 128.08, 125.53, 125.08, 120.47, 52.75, 44.67. HRMS (ESI): calcd for C₁₅H₁₃NO₃S [M+Na]⁺: 310.0514, found 310.0506.



(*R*)-ethyl 3-((S)-1-oxo-1-phenylpropan-2-yl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1ap) White solid, m.p.: 97.6-98.8 °C, , $[\alpha]_D^{20} = +50.3$ (c = 0.10, DCM), 37% yield and 94% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 90:10 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 16.675 min for (*S*)-isomer (minor), t_r = 22.439 min for (*R*)-isomer (major). ¹H NMR (500 MHz, Chloroform-*d*) δ 7.93 (d, *J* = 8.4 Hz, 2H),

7.81 (t, J = 7.2 Hz, 2H), 7.65-7.56 (m, 3H), 7.46 (t, J = 7.7 Hz, 2H), 6.14 (s, 1H), 4.44 (q, J = 7.1 Hz, 2H), 4.27 (q, J = 7.4 Hz, 1H), 1.49 (d, J = 7.4 Hz, 3H), 1.42 (t, J = 7.1 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 201.14, 169.13, 137.32, 137.30, 135.74, 133.69, 132.67, 130.57, 128.84, 128.62, 126.41, 121.68, 68.92, 63.53, 50.32, 14.73, 14.07. HRMS (ESI): calcd for C₁₉H₁₉NO₅S [M+Na]⁺ : 396.0882, found 396.0878.



(*R*)-ethyl 3-(1,1-difluoro-2-oxo-2-phenylethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1aq) White solid, m.p.: 115.3-117.1 °C, , $[\alpha]_D^{20}$ = +56.7 (c = 0.25, DCM), 44% yield and 64% ee, determined by chiral HPLC analysis (Chiralcel AD-H hexane/isopropanol, 70:30 v/v, 1.0 mL/min, UV 254 nm), retention times: t_r = 13.623 min for (*S*)-isomer (minor), t_r = 20.114 min for (*R*)-isomer (major). ¹H NMR (500 MHz, Chloroform-*d*) & 8.09 (d, *J* = 7.8 Hz, 2H), 7.98-7.93 (m, 1H), 7.87 (d, *J* = 8.5 Hz, 1H), 7.78-7.72 (m, 2H), 7.67 (t, *J* = 7.4 Hz, 1H), 7.51 (t, *J* = 7.8 Hz, 2H), 5.98 (s, 1H), 4.44-4.37 (m, 2H), 1.35 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) & 187.80 (dd, *J* = 32.1, 28.8 Hz), 165.61 (dd, *J* = 7.4, 2.2 Hz), 136.63, 135.26, 133.63, 131.84, 131.18 (t, *J* = 3.2 Hz), 130.44 (dd, *J* = 4.1, 2.2 Hz), 130.35 (d, *J* = 1.8 Hz),128.87, 127.06 (d, *J* = 5.6 Hz), 121.98, 115.43 (t, *J* = 269.8 Hz), 68.55 (dd, *J* = 26.0, 23.8 Hz), 64.44, 13.88. HRMS (ESI): calcd for C₁₈H₁₅F₂NO₅S [M+Na]⁺: 418.0537, found 418.0531.



(*R*)-ethyl 3-phenethyl-2,3-dihydrobenzo[*d*]isothiazole-3-carboxylate 1,1-dioxide (4) White solid, m.p.: 74.1-75.5 °C, $[\alpha]_D^{20} = +46.9$ (c = 0.25, DCM), 72% yield and 97% ee, determined by chiral HPLC analysis (Chiralcel OD-H hexane/isopropanol, 70:30 v/v, 0.8 mL/min, UV 254 nm), retention times: t_r = 9.739 min for (*R*)-isomer (major), t_r = 14.089 min (minor) for (*S*)-isomer. ¹H NMR (500 MHz, Chloroform-*d*) δ 7.58 (d, *J* = 7.9 Hz, 1H), 7.39 (s, 1H), 7.30 (d, *J* = 8.0 Hz, 1H), 7.21-7.16 (m, 2H), 7.10 (dd, *J* = 15.2, 7.2 Hz, 3H), 5.74 (s, 1H), 4.27-4.13 (m, 2H), 2.73-2.63 (m, 1H), 2.62-2.54 (m, 1H), 2.49-2.41 (m, 1H), 2.39 (s, 3H), 2.26-2.20 (m, 1H), 1.28 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 169.49, 144.15, 139.74, 137.98, 132.16, 130.95, 127.98, 127.96, 125.75, 124.51, 120.77, 68.30, 63.09, 41.56, 30.47, 21.39, 13.64. HRMS (ESI): calcd for C₁₉H₂₁NO₄S [M+Na]⁺: 382.1089, found 382.1081.





(R)-2'-(Pyridin-2-yl)-2,3-dihydro-5*'H*-spiro[indene-1,4'-oxazole] (L1a)







(*R*)-2'-(5-Methoxypyridin-2-yl)-2,3-dihydro-5'*H*-spiro[indene-1,4'-oxazole] (L1c)







Bis((R)-2,3-dihydro-5'H-spiro[indene-1,4'-oxazol]-2'-yl)propane (L3)





2,6-Bis((R)-2,3-dihydro-5'H-spiro[indene-1,4'-oxazol]-2'-yl)pyridine (L4)



(*R*)-ethyl 3-(2-oxo-2-phenylethyl)-2,3-dihydrobenzo[*d*]isothiazole -3-carboxylate 1,1-dioxide (1aa)



峰表

检测器 A	Ch1 254nm	峰表			
峰#	保留时间	面积	高度	面积 %	高度 %
1	14.861	5947858	144039	49.647	55.618
2	20.127	6032448	114940	50.353	44.382
总计		11980306	258980	100.000	100.000



1 检测器 A 通道1/254nm

峰表

检测器 A	Chl 254nm				
峰#	保留时间	面积	高度	面积 %	高度 %
1	15.142	202655	4826	0.325	0.433
2	19.892	62134110	1109354	99.675	99.567
总计		62336765	1114180	100.000	100.000

(R)-ethyl 5-methyl-3-(2-oxo-2-phenylethyl)-2,3-dihydrobenzo[d]isothiazole



-3-carboxylate 1,1-dioxide (1ba)





峰表

检测器 A	Ch1 254nm	峰表			
峰#	保留时间	面积	高度	面积 %	高度 %
1	11.735	1544441	40506	49.029	53.729
2	16.559	1605609	34884	50.971	46.271
总计		3150050	75390	100.000	100.000



1 检测器 A 通道1/254nm

. .

峰表

检测器 A	Ch1 254nm				
峰#	保留时间	面积	高度	面积 %	高度 %
1	11.937	81057	2095	0.582	0.700
2	16.372	13838300	297195	99.418	99.300
总计		13919358	299290	100.000	100.000

(R)-ethyl 5-methoxy-3-(2-oxo-2-phenylethyl)-2,3-dihydrobenzo[d]isothiazole



-3-carboxylate 1,1-dioxide (1ca)




检测器 A	Ch1 254nm		暉大		
峰#	保留时间	面积	高度	面积 %	高度 %
1	14.920	1039324	20877	49.834	52.638
2	20.139	1046257	18785	50.166	47.362
总计		2085581	39662	100.000	100.000



峰表 检测器 A Ch1 254nm 峰# 保留时间 1 15.062 2 19.906 总计 面积 113477 10293229 10406706 高度 2476 174255 176731 面积 % 1.090 98.910 100.000 高度 % 1.401 98.599 100.000 (R)-ethyl 5-(tert-butyl)-3-(2-oxo-2-phenylethyl)-2,3-dihydrobenzo[d]isothiazole









检测器 A	Ch1 254nm		峰表		
峰#	保留时间	面积	高度	面积 %	高度 %
1	7.874	962873	39663	50.063	63.831
2	14.237	960460	22474	49.937	36.169
总计		1923333	62137	100.000	100.000



 峰表
 峰表

 峰#
 保留时间
 面积
 高度
 面积%
 高度%

 1
 7.487
 222412
 10310
 1.179
 2.014

 2
 13.062
 18641668
 501745
 98.821
 97.986

 总计
 18864080
 512055
 100.000
 100.000

(*R*)-ethyl 5-chloro-3-(2-oxo-2-phenylethyl)-2,3-dihydrobenzo[*d*]isothiazole



-3-carboxylate 1,1-dioxide (1ea)





检测器 A	Ch1 254nm		峰表		
峰#	保留时间	面积	高度	面积 %	高度 %
1	15.082	842422	13386	50.445	54.790
2	22.084	827553	11045	49.555	45.210
总计		1669975	24431	100.000	100.000



检测器 A	峰表 Ch1 254nm							
峰#	保留时间	面积	高度	面积 %	高度 %			
1	15.386	60961	1034	0.523	0.639			
2	21.657	11586788	160829	99.477	99.361			
总计		11647748	161863	100.000	100.000			

(R)-ethyl 3-(2-oxo-2-phenylethyl)-5-(trifluoromethyl)-2,3-dihydrobenzo[d]



isothiazole-3-carboxylate 1,1-dioxide (1fa)



1 检测器 A 通道1/254nm

检测器 A	Ch1 254nm	峰表 Ch1 254nm							
峰#	保留时间	面积	高度	面积 %	高度 %				
1	8.835	3371592	140953	49.852	63.347				
2	16.184	3391599	81556	50.148	36.653				
总计		6763191	222510	100.000	100.000				



峰表 检测器 A Ch1 254nm 峰# 保留时间 1 8.895 2 16.202 面积 205011 31607235 31812246 高度 11600 718418 730017 面积 % 0.644 99.356 100.000 高度 % 1.589 98.411 100.000 2 总计

(R)-ethyl 3-(2-oxo-2-(4-tolyl)ethyl)-2,3-dihydrobenzo[d] isothiazole









检测器 A	Ch1 254nm		峰表		
峰#	保留时间	面积	高度	面积 %	高度 %
1	20.340	706770	9088	49.118	56.006
2	24.146	732148	7139	50.882	43.994
总计		1438918	16227	100.000	100.000



检测器 A	Ch1 254nm				
峰#	保留时间	面积	高度	面积 %	高度 %
1	20.138	475846	8290	1.773	2.721
2	22.912	26366274	296338	98.227	97.279
总计		26842120	304629	100.000	100.000

(R)-ethyl 3-(2-(4-methoxyphenyl)-2-oxoethyl)-2,3-dihydrobenzo[d]isothiazole



-3-carboxylate 1,1-dioxide (1ac)





金测器 A	Ch1 254nm		峰表		
峰#	保留时间	面积	高度	面积 %	高度 %
1	23.936	953153	12127	49.979	54.663
2	30.109	953941	10058	50.021	45.337
总计		1907094	22185	100.000	100.000



检测器 A	Ch1 254nm		「単手イ	×	
峰#	保留时间	面积	高度	面积 %	高度 %
1	22.639	12886642	175070	99.417	99.444
2	29.657	75573	979	0.583	0.556
总计		12962214	176048	100.000	100.000

(R)-ethyl 3-(2-(4-fluorophenyl)-2-oxoethyl)-2,3-dihydrobenzo[d]isothiazole



-3-carboxylate 1,1-dioxide (1ad)





检测器 A	峰表 Cb1_254pm							
峰#	保留时间	面积	高度	面积 %	高度 %			
1	13.729	10951424	268133	49.521	61.507			
2	19.259	11163219	167810	50.479	38.493			
总计		22114643	435943	100.000	100.000			



检测器 A	Ch1 254nm				
峰#	保留时间	面积	高度	面积 %	高度 %
1	13.268	7451167	197458	98.538	99.173
2	19.243	110524	1647	1.462	0.827
总计		7561692	199104	100.000	100.000

(R)-ethyl 3-(2-(4-chlorophenyl)-2-oxoethyl)-2,3-dihydrobenzo[d]isothiazole









	峰表						
位测希 A	Ch1 254nm						
峰#	保留时间	面积	高度	面积 %	高度 %		
1	15.458	4547351	93882	49.755	58.783		
2	20.838	4592090	65827	50.245	41.217		
总计		9139440	159709	100.000	100.000		



峰表 检测器 A Ch1 254nm 峰# 保留时间 1 15.342 2 21.386 面积 % 98.482 1.518 100.000 面积 20239974 311910 20551885 高度 425240 6251 431490 高度 % 98.551 1.449 100.000

2 总计

(*R*)-ethyl 3-(2-oxo-2-(4-(trifluoromethyl)phenyl)ethyl)-2,3-dihydrobenzo[*d*]



isothiazole-3-carboxylate 1,1-dioxide (1af)





检测器 A	Ch1 254nm		峰表		
峰#	保留时间	面积	高度	面积 %	高度 %
1	13.276	8730102	200051	49.907	65.879
2	19.636	8762581	103615	50.093	34.121
总计		17492683	303666	100.000	100.000



检测器 A	Ch1 254nm		嘽衣		
峰#	保留时间	面积	高度	面积 %	高度 %
1	15.730	1589715	25383	99.363	99.616
2	21.503	10184	98	0.637	0.384
总计		1599899	25481	100.000	100.000

(R)-ethyl 3-(2-oxo-2-(3-tolyl)ethyl)-2,3-dihydrobenzo[d]isothiazole -3-carboxylate

1,1-dioxide (1ag)







检测	则器 A	Ch1 254nm		叫手衣		
l	峰#	保留时间	面积	高度	面积 %	高度 %
	1	14.690	5610837	120963	51.964	66.137
	2	24.725	5186669	61935	48.036	33.863
	总计		10797506	182897	100.000	100.000



 检测器 A Ch1 254nm
 峰本
 面积
 高度
 面积%
 高度%

 峰本
 保留时间
 面积
 高度
 3.081
 6.150

 1
 15.028
 1207153
 28930
 3.081
 6.150

 2
 24.494
 37967430
 441509
 96.919
 93.850

 总计
 39174583
 470439
 100.000
 100.000

(R)-ethyl 3-(2-(3-methoxyphenyl)-2-oxoethyl)-2,3-dihydrobenzo[d]



isothiazole-3-carboxylate 1,1-dioxide (1ah)







检测器 A	Ch1 254nm		₩ ₽ 4X		
峰#	保留时间	面积	高度	面积 %	高度 %
1	13.381	2055418	49516	2.682	10.702
2	40.464	74580817	413172	97.318	89.298
总计		76636235	462688	100.000	100.000

(R)-ethyl 3-(2-(3-chlorophenyl)-2-oxoethyl)-2,3-dihydrobenzo[d]isothiazole









1 检测器 A 通道1/254nm

 峰表

 检测器 A Ch1 254nm
 面积
 高度
 面积 %
 高度 %

 峰#
 保留时间
 面积
 25294
 50.729
 62.080

 1
 22.474
 2005817
 25294
 50.729
 62.080

 2
 36.560
 1948186
 15450
 49.271
 37.920

 总计
 3954003
 40744
 100.000
 100.000



恒测着 A	Ch1 254nm				
峰#	保留时间	面积	高度	面积 %	高度 %
1	21.784	609510	6998	2.263	3.060
2	33.071	26319093	221646	97.737	96.940
总计		26928603	228644	100.000	100.000

(R)-ethyl 3-(2-oxo-2-(2-tolyl)ethyl)-2,3-dihydrobenzo[d]isothiazole -3-carboxylate

1,1-dioxide (1aj)





1 检测器 A 通道1/254nm

检测器 A	Ch1 254nm		峰表		
峰#	保留时间	面积	高度	面积 %	高度 %
1	11.045	15928609	540714	49.701	59.424
2	17.014	16120497	369207	50.299	40.576
总计		32049106	909921	100.000	100.000



(R)-ethyl 3-(2-(2-methoxyphenyl)-2-oxoethyl)-2,3-dihydrobenzo[d]isothiazole



-3-carboxylate 1,1-dioxide (1ak)





检测器 A	Ch1 254nm		~= 1X		
峰#	保留时间	面积	高度	面积 %	高度 %
1	38.149	4450958	69077	50.008	56.721
2	49.708	4449585	52706	49.992	43.279
总计		8900543	121783	100.000	100.000



检测器 A	Ch1 254nm				
峰#	保留时间	面积	高度	面积 %	高度 %
1	38.396	363561	6648	1.824	2.884
2	50.468	19568794	223864	98.176	97.116
总计		19932355	230512	100.000	100.000

(R)-ethyl 3-(2-(2-bromophenyl)-2-oxoethyl)-2,3-dihydrobenzo[d]isothiazole



-3-carboxylate 1,1-dioxide (1al)





I 位测岙 A 迪坦 1/254nm	n	
--------------------	---	--

检测器 A	Ch1 254nm		峰表		
峰#	保留时间	面积	高度	面积 %	高度 %
1	17.650	11759194	204457	50.458	61.692
2	35.976	11545939	126957	49.542	38.308
总计		23305133	331414	100.000	100.000



险测器 A	Ch1 254nm				
峰#	保留时间	面积	高度	面积 %	高度 %
1	18.290	944502	21588	1.793	3.767
2	36.347	51745338	551531	98.207	96.233
总计		52689840	573118	100.000	100.000

(R)-ethyl 5-methoxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)-2,3-dihydrobenzo[d]











检测器 A	Ch1 254nm		峰表		
峰#	保留时间	面积	高度	面积 %	高度 %
1	20.007	1677070	18480	50.157	57.704
2	28.232	1666542	13545	49.843	42.296
总计		3343611	32025	100.000	100.000



检测器 A	Ch1 254nm				
峰#	保留时间	面积	高度	面积 %	高度 %
1	18.830	38359718	435881	98.739	99.160
2	28.530	490085	3694	1.261	0.840
总计		38849803	439575	100.000	100.000

(R)-ethyl 3-(2-(4-chlorophenyl)-2-oxoethyl)-5-methoxy-2,3-dihydrobenzo[d]



isothiazole-3-carboxylate 1,1-dioxide (1an)





检测器 A	Ch1 254nm		峰表		
峰#	保留时间	面积	高度	面积 %	高度 %
1	16.807	31194504	567990	49.925	66.815
2	20.536	31288125	282107	50.075	33.185
总计		62482629	850097	100.000	100.000



检测器 A	Ch1 254nm		軍人		
峰#	保留时间	面积	高度	面积 %	高度 %
1	16.984	48401	785	0.300	0.408
2	20.709	16092418	191535	99.700	99.592
总计		16140819	192320	100.000	100.000

Ethyl 4-(2-oxo-2-phenylethyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine-4-



carboxylate 2,2-dioxide (1ga)



 峰濃
 峰濃
 峰濃
 保留时间
 面积
 高度
 面积 %
 高度 %

 1
 23.075
 2147179
 13586
 50.728
 52.146

 2
 30.539
 2085587
 12468
 49.272
 47.854

 总计
 4232766
 26054
 100.000
 100.000



检测器 A	Ch1 254nm	"# A				
峰#	保留时间	面积	高度	面积 %	高度 %	
1	21.361	25222970	178034	86.478	87.646	
2	30.033	3943942	25094	13.522	12.354	
总计		29166912	203129	100.000	100.000	

2-(2,2-dioxido-3,4-dihydrobenzo[*e*][1,2,3]oxathiazin-4-yl)-1-phenylethanone

(1ha)




检测器 A	Ch1 254nm		峰衣		
峰#	保留时间	面积	高度	面积 %	高度 %
1	9.301	1522530	35527	49.111	56.109
2	13.183	1577683	27791	50.889	43.891
总计		3100213	63318	100.000	100.000



检测器 A	唯衣 Ch1 254nm							
峰#	保留时间	面积	高度	面积 %	高度 %			
1	12.003	14096828	409530	58.178	62.248			
2	14.367	10133855	248368	41.822	37.752			
总计		24230683	657898	100.000	100.000			

(R)-methyl 3-(2-oxo-2-phenylethyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate

1,1-dioxide (1ia)









1 检测器 A 通道1/254nm

检测器 A	Ch1 254nm		峰表		
峰#	保留时间	面积	高度	面积 %	高度 %
1	22.301	4555618	59577	51.951	72.678
2	46.290	4213462	22397	48.049	27.322
总计		8769080	81974	100.000	100.000



检测器 A	Ch1 254nm		峰衣		
峰#	保留时间	面积	高度	面积 %	高度 %
1	22.754	460760	7140	0.998	2.568
2	44.140	45727487	270852	99.002	97.432
总计		46188246	277992	100.000	100.000



(*R*)-2-(1,1-dioxido-2,3-dihydrobenzo[*d*]isothiazol-3-yl)-1-phenylethanone (1ja)

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm) --200



检测器 A	Ch1 254nm		峰	表	
峰#	保留时间	面积	高度	面积 %	高度 %
1	37.332	2134060	37251	50.007	54.232
2	44.664	2133421	31437	49.993	45.768
总计		4267482	68688	100.000	100.000



检测器 A	Ch1 254nm	峰衣					
峰#	保留时间	面积	高度	面积 %	高度 %		
1	38.289	919771	15445	16.741	19.417		
2	46.120	4574356	64100	83.259	80.583		
总计		5494127	79545	100.000	100.000		

(R)-ethyl 3-((S)-1-oxo-1-phenylpropan-2-yl)-2,3-dihydrobenzo[d]isothiazole



-3-carboxylate 1,1-dioxide (1ap)

200

190 180

170 160

150 140 130 120

10

110



检测器 A	Ch1 254nm		峰老	長	
峰#	保留时间	面积	高度	面积 %	高度 %
1	14.131	3847105	55686	50.626	53.678
2	20.911	3752004	48055	49.374	46.322
总计		7599110	103741	100.000	100.000



小面瓜本	III 054						
恒测岙 A	Ch1 254nm						
峰#	保留时间	面积	高度	面积 %	高度 %		
1	16.675	284806	4696	2.785	3.448		
2	22.439	9943051	131483	97.215	96.552		
总计		10227857	136179	100.000	100.000		

(R)-ethyl 3-(1,1-difluoro-2-oxo-2-phenylethyl)-2,3-dihydrobenzo[d]isothiazole



-3-carboxylate 1,1-dioxide (1aq)





检测器 A	Ch1 254nm		峰	表	
峰#	保留时间	面积	高度	面积 %	高度 %
1	13.794	1168037	41162	50.033	60.387
2	20.068	1166512	27002	49.967	39.613
总计		2334549	68164	100.000	100.000



the state of the s					
峰#	保留时间	面积	高度	面积 %	高度 %
1	13.625	3641993	126843	17.869	25.734
2	20.114	16739240	366066	82.131	74.266
总计		20381233	492909	100.000	100.000

(R)-ethyl 3-phenethyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide



82





检测器 A	Ch1 254nm				
峰#	保留时间	面积	高度	面积 %	高度 %
1	9.893	1585621	37703	49.958	56.274
2	14.037	1588287	29296	50.042	43.726
总计		3173908	67000	100.000	100.000



1 检测器 A 通道1/254nm

检测器	A Ch1 254nm		峰え	 定	
峰#	保留时间	面积	高度	面积 %	高度 %
1	9.739	7470785	190500	98.566	98.902
2	14.089	108690	2115	1.434	1.098
总记	+	7579476	192614	100.000	100.000

5. References

- [1] D. Connors, N. Goroff, Org. Lett. 2016, 18, 4262.
- [2] Q. H. Shao, L. Wu, J. Z. Chen, I. D. Gridnev, G. Q. Yang, F. Xie, W. B. Zhang,Adv. Synth. Catal. 2018, 360, 4625.
- [3] R. Warmuth, T. E. Munsch, R. A. Stalker, B. Li, A. Beatty, Tetrahedron 2001, 57,6383.
- [4] (a) Y. F. Gao, Z. X. Qiu, R. Sun, N. X. Gao, G. R. Cao, D. W. Teng, Tetrahedron Lett. 2018, 59, 3938.
- (b) N. X. Gao, Y. S. Li, G. R. Cao, D. W. Teng, New J. Chem. 2021, 45, 16477.